This page is updated frequently with new Embryonic Stem Cell-related patent applications.
|Lineage differentiation of encapsulated embryonic stem cells|
This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (es) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (ra) into the permeable microcapsule system.
Rutgers, The State University Of New Jersey
|Mammalian embryonic stem cell isolated from a homogeneous pluripotent outgrowth of a mammalian pre-implantation embryo|
The present invention relates to a method of isolating a pluripotent cell from a pre-implantation embryo including one or more pluripotent cells. The method includes propagating the one or more pluripotent cells from the embryo under conditions that allow undifferentiated growth of the one or more pluripotent cells and do not allow growth of non-pluripotent cells from the embryo..
Icmstemcell Pty Ltd
|Differentiation of human embryonic stem cells|
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells, wherein greater than 85% of the cells in the population express markers characteristic of the definitive endoderm lineage..
Janssen Biotech, Inc.
|Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells|
A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix.
|Differentiation of human embryonic stem cells into pancreatic endocrine cells|
The present invention provides methods to promote differentiation of pancreatic endoderm cells to pancreatic endocrine rich clusters and to enhance insulin expression in hormone-expressing cells.. .
Janssen Biotech, Inc.
|Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells|
The present disclosure relates to compositions and methods comprising cell surface markers for hes-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hes cells.. .
|Stem cell culture medium and method|
Stem cells such as embryonic stem cells (es cells), including human es cells, are cultured in a medium comprising a rock inhibitor, and a stem cell culture medium, optionally serum free, comprises a rock inhibitor.. .
|Differentiation of human embryonic stem cells|
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells, wherein greater than 80% of the cells in the population express markers characteristic of the definitive endoderm lineage..
Janssen Biotech, Inc.
|Method for inducing pluripotency in a hematopoietic cell|
There is provided a method of inducing pluripotency in a hematopoietic cell. The method comprises providing a blood sample that has been collected from a subject in the absence of any polysaccharide preparation used for separating blood components.
Agency For Science, Technology And Research
|Methods for nuclear reprogramming using synthetic transcription factors|
The current disclosure provides methods for reprogramming mammalian somatic cells by regulating the expression of endogenous cellular genes. Cellular reprogramming of somatic cells can be induced by activating the transcription of embryonic stem cell-associated genes (e.g., oct3/4) and suppressing the transcription of somatic cell-specific and/or cell death-associated genes.
Lonza Walkersville, Inc.
Composition for preventing and treating acetaminophen inducing hepatotoxicity containing tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine) as an effective ingredient
The present invention relates to a composition for the prevention and treatment of liver toxicity originated from acetaminophen comprising tnp (n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine) as an active ingredient. The present inventors confirmed that tnp known as a 5-inosito pyrophosphate inhibitor suppressed apoptosis caused by acetaminophen in human embryonic stem cell-derived liver cells, mouse liver cells, and human hepatoma cell lines, up-regulated glutathione converted in liver cells, and inhibited jnk phosphorylation that is a kind of response against stress increased by acetaminophen.
Korea Advanced Institute Of Science And Technology
Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases
The present disclosure relates to methods for producing dopaminergic cells and evaluating their functionality. When pluripotent human embryonic stem cells are cultured on plates coated with laminin-111, laminin-121, laminin-521, laminin-421, or laminin-511 in cell culture medium containing a gsk3 inhibitor and a tgf-β inhibitor as well as timely administered fibroblast growth factor, desired neural cells are produced at far higher rates.
Avian induced pluripotent stem cells and their use
The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc.
University Of Georgia Research Foundation, Inc.
Anti-fzd10 monoclonal antibodies and methods for their use
The present invention relates generally to anti-fzd10 antibodies and to methods of using anti-fzd10 antibodies. In particular, the anti-fzd10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of fzd10, including as stand-alone therapies and in combination therapies with other agents..
Media for culturing stem cells
Well-defined, xeno-free culture media which comprise a tgf-beta isoform or the chimera formed between il6 and the soluble il6 receptor (il6ril6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media.
Technion Research & Development Foundation Limited
Monoclonal antibody capable of binding integrin alpha 10 beta 1
The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular i-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the deutsche sammlung von microorganismen und zellkulturen gmbh under the accession number dsm acc2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular i-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited.
Medium comprising transforming growth factor beta 1 and basic fibroblast growth factor
The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.. .
Technion Research & Development Foundation Limited
Directed cardiomyocyte differentiation and ventricular specification of stem cells
Disclosed is a fully chemically defined, small molecule-mediated, directed differentiation system that promotes differentiation of stem cells, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, such as human forms of these stem cell types, to ventricular cardiomyocytes in a highly efficient, reproducible and scalable fashion. Also disclosed is a cost-effective and efficient protocol, or method, for generating cardiomyocytes and a cost-effective and efficient method of maturing cardiomyocytes.
The University Of Hong Kong
Compositions and methods for promoting the generation of pdx1+ pancreatic cells
Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in table i to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described..
The General Hospital Corporation
Duck embryonic derived stem cell lines for the production of viral vaccines
The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the ebx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses.
Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
Methods for producing substantially pure cultures of human neural retinal progenitor cells, forebrain progenitor cells, and retinal pigment epithelial cells are disclosed. In addition, the successful differentiation of human embryonic stem cells and human induced pluripotent stem cells through the major developmental stages of human retinogenesis is disclosed..
Wisconsin Alumni Research Foundation
Methods of mammalian retinal stem cell production and applications
The invention provides an in vitro method for producing isolated mammalian primitive retinal stem cells (prscs) comprising: (a) culturing isolated embryonic stem cells (escs) from a mammal in a cell culture medium that is free of feeder cells, feeder-conditioned medium or serum so as to produce and grow a culture of the isolated escs; and (b) contacting the culture of the isolated escs so grown with one or more of an inhibitor for wnt or tgf-β/bmp signaling so as to differentiate the isolated escs of (a) into primitive retinal stem cells thereby producing isolated mammalian prscs.. .
The Regents Of The University Of California
Super-enhancers and methods of use thereof
The present invention relates in some aspects to super-enhancers and related compositions, methods, and agents that are useful for modulating expression of cell type-specific genes that are required for maintenance of cell identity (e.g., embryonic stem cell identity) or maintenance of a disease state (e.g., cancer).. .
Whitehead Institute For Biomedical Research
Isolation of non-embryonic stem cells and uses thereof
The invention described herein relates to methods of isolating non-embryonic stem cell, e.g., adult stem cell, from a non-embryonic tissue, e.g., an adult tissue or organ. Non-embryonic stem cells (e.g., adult stem cells) thus isolated from the various tissues or organs can self-renew or propagate indefinitely in vitro, are multipotent and can differentiate into the various differentiated cell types normally found within the tissue or organ from which the stem cells are isolated.
The Jackson Laboratory
Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
Provided are compositions and methods that relate to prophylaxis and therapy of angiogenesis associated disease and includes novel knockin mice which express novel human/mouse chimeric endoglin, vectors for use in making such mice, and murine embryonic stem cells comprising the novel human/mouse transgene. Also provided are anti-human endoglin monoclonal antibodies (mabs) which can be used as antiangiogenic agents for prophylaxis or therapy of human tumor angiogenesis and human angiogenesis-associated diseases having excessive vascularization.
Health Research, Inc.
Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method
The present disclosure relates to a method for inducing pluripotent stem cells by inducing reprogramming and/or dedifferentiation of differentiated adult cells using shikimic acid, a plant extract or plant stem cells containing shikimic acid and an extract of dedifferentiated stem cells (callus), pluripotent stem cells prepared by the method and a composition containing the pluripotent stem cells. In accordance with the present disclosure, ethical concerns implicated with the use of eggs to prepare pluripotent stem cells such as embryonic stem cell can be resolved.
Seoul National University R&db Foundation
Method of nociceptor differentiation of human embryonic stem cells and uses thereof
The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hesc), human induced pluripotent stem cells (hipsc), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hesc and/or hipsc to nociceptors (i.e.
Memorial Sloan Kettering Cancer Center
Patient-specific stem cell lines derived from human parthenogenetic blastocysts
Methods are disclosed for generating hla homozygous parthenogenetic human stem cell (hpsc-hhom) lines from both hla homozygous and hla heterozygous donors. These hpsc-hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity.
Flk1+ and ve-cadherin+ endothelial cells derived from ips or es cells, and methods of preparing and using the same
This invention provides endothelial cells expressing transcription factor er71/etv2, and cell surface endothelial markers flk1 and ve-cadherin prepared from induced pluripotent stem cells or embryonic stem cells, as well as methods of preparing the cells and methods of using the cells to vascularize and re-endothelialize or repair ischemic tissue in a subject.. .
The Board Of Trustees Of The University Of Illinois
Method for selecting a permissive cell line for replicating avian viruses
The present invention relates to a method for obtaining an untransformed avian cell line enabling in vitro avian virus replication. Said method includes the following steps: a) culturing avian embryonic stem cells in the presence of a stroma for at least 3 days; b) culturing for at least 2 days in a medium having a low serum concentration; c) culturing for at least 2 days in a medium having a low serum concentration containing 1 to 10 mm of hexamethyleme bisacetamide (hmba); d) culturing for at least 10 days in a medium having a low serum concentration; and e) culturing or freezing an avian cell line enabling avian virus replication.
Institut National De La Recherche Agronomique
Composition for preventing and treating liver fibrosis or liver cirrhosis, containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells
The present invention relates to a composition for preventing and/or treating liver fibrosis or liver cirrhosis, which contains, as an active ingredient, mesenchymal stem cells derived from human embryonic stem cells. In the present invention, it was confirmed that mesenchymal stem cells derived from human embryonic stem cells have a preventive effect against liver fibrosis.
Seoul National University Hospital
Method for differentiation of pluripotent stem cells into multi-competent renal precursors
This application relates to a method for differentiating pluripotent stem cells (pscs) into multi-competent renal precursor cells expressing six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes.
Hoffmann-la Roche Inc.
Human multipotent embryonic stem cell-like progenitor cells
The invention provides a plurality of embryonic stem cell-like progenitor cells, which are isolated from a human tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of cd34, cd117, cd133, cd201, globoh and combination thereof, and cultured in a medium supplemented with at least one or more steroids and one or more growth factors. The cells of the invention express cd34 and exhibit sphere-like clonogenicity in early passages and express multipotent embryonic stem cells (escs) like characteristics..
Sunshine Life Science & Technology Corp.
Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes
The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells. The invention also provides mixed cell populations enriched for a target cell phenotype where the mixed cell population comprises the differentiated in vitro progeny of primate embryonic stem cells..
Asterias Biotherapeutics, Inc.
Parthenogenic activation of human oocytes for the production of human embryonic stem cells
Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of o2 tension, including manipulation of ca2+ under high o2 tension and contacting oocytes with serine threonine kinase inhibitors under low o2 tension, isolating inner cell masses (icms) from the activated oocytes, and culturing the cells of the isolated icms under high o2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing icm/stem cells.
International Stem Cell Corporation